Dexcom and the Race to Non-Invasive Glucose Monitoring

Dexcom leads glucose monitoring in the AI Biotech Patent Forecast® with 48 patent assets as shown in the radian above. So far, the company’s main focus has been making its continuous glucose monitoring (CGM) systems compatible with major players in the diabetes device industry. Its current product, the Dexcom G6 CGM System, is a small sensor wire placed under the skin and held in place by a patch. The system sends real-time readings to a receiver, and is compatible with smart devices with the CGM app. However, new doors are opening due to FDA approval in June 2021 of Dexcom’s web-based APIs, which will enable more digital health companies to feed Dexcom’s CGM data into their own health apps and devices. 

Dexcom is also working to make CGM less invasive with its new system, the G7. The company has announced that the G7 will be 60% smaller than the G6 and equipped with an all-in-one sensor, applicator, and transmitter allowing it to connect to a broader range of devices. With the FDA approved APIs and the new CGM system, Dexcom has partnered with Garmin to provide real-time glucose monitoring to runners, cyclists, and others. This is an important step toward making glucose monitoring more accessible and broadening the field of people who want to log their blood sugar levels. 

These advancements by Dexcom have great potential and will likely affect the ongoing race between smartwatch device leaders, Fitbit, Apple, and Samsung, to implement noninvasive glucose monitoring. Apple is currently the favorite in this race due to its partnership with Rockley Photonics, which announced its “clinic-on-the-wrist” sensors in July 2021. The new sensors use light based detectors to capture a person’s hydration, muscle lactate, blood alcohol, and glucose levels, however it is uncertain how accurate the sensors are at this time. Additionally, prior to its acquisition by Google, Fitbit took part in research with Dexcom in which patients’ activity was compared to their glucose data. Fitbit has also invested $6M in Sano, a company that is working on a painless coin-sized patch to track glucose.  

As Dexcom continues to dominate the glucose monitoring arena and improve its CGM systems to be more comfortable, less invasive, and compatible with more devices, Apple, Fitbit, or Samsung are likely going to try to be part of future partnerships. Additionally, since Dexcom currently dominates the patent space, it will be difficult for the companies Apple and Fitbit currently work with to catch up. 

To keep up with these companies and the future of glucose monitoring check out the AI Biotech Patent Forecast®!